STOCKS TELEGRAPH

Category: Mid Day Movers

  • Draganfly (DPRO) Lands Major Pentagon Deal, Stock Jumps

    Draganfly (DPRO) Lands Major Pentagon Deal, Stock Jumps

    Draganfly Inc. (NASDAQ: DPRO) shares surged 23.84% to trade at $4.47 as of the last check today, following the company’s announcement of a critical defense delivery order award involving its flagship drone platform.

    Commander3 XL Chosen by U.S. Department of Defense

    Draganfly (DPRO) announced that a major division of the US Department of Defense (DoD) has chosen its Commander3 XL (C3XL) unmanned aerial vehicle (UAV), commonly known as the “Swiss Army Knife” of drones. The DoD’s changing deployment tactics, which are focused on improved field-operational and reconnaissance capabilities, are supported by this milestone selection.

    Draganfly maintained direct contact with military end users to tailor the UAV to particular mission needs, and the order was processed through a reputable prime contractor. This collaboration ensures the Commander3 XL meets operational expectations in real-world defense scenarios.

    Increased Participation in ISR Missions

    For intelligence, surveillance, and reconnaissance (ISR) missions that need flexible and dynamic UAV systems, the Commander3 XL is being used. Its participation in ongoing defense initiatives highlights the rising need for platforms that blend high-performance capabilities with tactical adaptability.

    The C3XL is becoming more and more acknowledged as a dependable tool for critical military, security, and emergency response missions because of its great flight endurance, modular payload flexibility, and mission-specific customisation. The DoD’s choice solidifies Draganfly’s standing as a frontrunner in UAV defensive technology.

    SMEX25 Success Demonstrates Advanced Logistics Capabilities

    Alongside this accomplishment, Draganfly also took part in the Sustainment Modernization Experiment 2025 (SMEX25) of the U.S. Army, which was organized in collaboration with TB2 Aerospace. Autonomously deploying, retrieving, and recharging TB2’s tactical resupply pods during the exercise was 100% successful due to DPRO’s Commander3 XL’s flawless integration with the Drone Recharging Operational Payload System (DROPS).

    This accomplishment demonstrated the DROPS system’s revolutionary potential for military logistics in disputed areas in addition to validating it under demanding field conditions. Defense assessors praised the demonstration, which furthered Draganfly’s expanding contribution to autonomous supply chain innovation for contemporary conflict.

  • Monogram (MGRM) Secures Buyout Deal, Stock Reacts Strongly

    Monogram (MGRM) Secures Buyout Deal, Stock Reacts Strongly

    Monogram Technologies Inc. (NASDAQ: MGRM) shares are experiencing a substantial rally on the U.S. stock charts today, rising 73.40% to reach $5.71 at the time of last check. The dramatic surge in MGRM stock follows the announcement of a definitive merger agreement with Zimmer Biomet, under which Zimmer will acquire all outstanding shares of Monogram for an upfront cash payment of $4.04 per share. This values the company’s equity at approximately $177 million and its enterprise value at roughly $168 million.

    Additional Value via Contingent Rights

    A non-tradeable contingent value right (CVR) will be awarded to Monogram common shareholders in addition to the original cash payment. Holders of this CVR are eligible to earn an extra $12.37 in cash per share, subject to the fulfillment of certain revenue, regulatory, and product development milestones through 2030. The transaction has received unanimous approval from both MGRM’s and Zimmer Biomet’s boards of directors.

    Revolutionizing Surgical Robotics

    Monogram’s cutting-edge CT-based, semi-autonomous robotic system for total knee arthroplasty (TKA), which integrates artificial intelligence for navigation, received FDA 510(k) clearance in March 2025. It is slated for commercialization using Zimmer Biomet implants by early 2027. MGRM is also developing a fully autonomous robotic solution with the potential to significantly enhance safety, precision, and clinical outcomes across a broader range of surgical procedures.

    Strategic Integration and Future Prospects

    Following the completion of the transaction, Zimmer Biomet aims to become the first company in orthopedics to provide a fully autonomous surgical robot. Monogram’s proprietary robotic technology will augment Zimmer Biomet’s ROSA Robotics platform and strengthen its already diverse and surgeon-focused suite of technologies.

    With Zimmer Biomet’s global reach and infrastructure, MGRM’s innovations are expected to scale rapidly. The acquisition will be financed through Zimmer Biomet’s cash reserves and available debt facilities, with no expected disruption to its capital allocation strategy. The deal is pending regulatory and shareholder approvals, with the closing anticipated later in 2025.

  • MiNK Therapeutics (INKT) Stock Soars On Landmark Case Report

    MiNK Therapeutics (INKT) Stock Soars On Landmark Case Report

    In early trading, shares of MiNK Therapeutics, Inc. (NASDAQ: INKT) jumped 548.51% to $50.13 after a notable case report was published in Nature’s Oncogene.

    Therapeutic Potential

    The study reported a complete and long-lasting remission in a patient with advanced, treatment-resistant testicular cancer following treatment with an allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797. As part of its clinical research (NCT05108623), MiNK Therapeutics revealed that the case was included in the publication “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor.”

    The patient had not responded to a number of therapies, including platinum-based chemotherapy, autologous stem cell transplantation, and multiple immune checkpoint inhibitors, including anti-PD-1, anti-CTLA-4, and anti-TIGIT. After a single infusion of agenT-797 with nivolumab, the patient obtained a complete clinical, radiologic, and biochemical remission and remained disease-free for almost two years.

    Donor iNKT cells remained detectable for six months following treatment, and the therapy showed a satisfactory safety profile with neither cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).

    Growing Clinical Support for agenT-797

    The remarkable remission case adds to a mounting body of evidence supporting agenT-797’s efficacy in solid tumors. MiNK Therapeutics reported Phase 2 findings in second-line (2L) gastric cancer at the 2025 AACR Immuno-Oncology meeting. These data showed early tumor reduction, tumor infiltration, and immune activation in patients who had not responded to checkpoint inhibitors before.

    Notably, a number of study participants had longer survival times than 12 months, which is uncommon in situations with such advanced malignancy.

    Continued Progress

    A further peer-reviewed case involving a patient with metastatic gastric cancer who received a single dosage of agenT-797 with nivolumab shown a 42% tumor shrinkage and more than nine months of progression-free survival, further supporting the therapy, was also reported by Oncogene.

    The therapy’s potential to improve outcomes for resistant solid tumors is further supported by the fact that MiNK Therapeutics’ current Phase 2 study in gastric cancer (NCT06251973) is still available for recruitment and that more clinical readouts are anticipated soon.

  • GameSquare (GAME) Gains Investor Attention Amid Treasury Management Shift

    GameSquare (GAME) Gains Investor Attention Amid Treasury Management Shift

    Following the announcement of a substantial financial and strategic development, GameSquare Holdings, Inc. (NASDAQ: GAME) had a notable market rise. The price of GAME’s shares as of the most recent trading session was $2.19, indicating a remarkable 42.16% increase.

    The company’s announcement of a newly priced underwritten public offering, in which it would issue 8,421,054 common shares at $0.95 per share, comes after this noteworthy increase. Gross profits from the transaction are expected to be around $8 million.

    Proceeds Target Ethereum Treasury and DeFi Initiatives

    The raised capital will primarily support the launch of GameSquare’s Ethereum (ETH)-centered treasury management strategy, marking a significant step in its diversification and growth roadmap.

    This initiative is being undertaken in collaboration with Dialectic, a globally recognized firm specializing in crypto-native capital management. The move signals GameSquare’s entry into the decentralized finance (DeFi) sector, aiming to derive real-time, on-chain yield while broadening its crypto capabilities.

    High-Yield Strategy Anchored in Advanced Technology

    Central to this strategy is the Medici platform, developed by Dialectic, which integrates machine learning algorithms, automated optimization processes, and advanced risk management protocols. GameSquare aims to achieve annualized yields between 8–14%, significantly outpacing traditional ETH staking returns of 3–4%.

    To improve and stabilize returns, this yield-focused treasury model may potentially diversify into other Ethereum-based assets, such as stablecoins and non-fungible tokens (NFTs).

    Board-Backed Crypto Allocation and Long-Term Vision

    The GameSquare Board has endorsed an ETH investment cap of up to $100 million, to be allocated in stages while preserving sufficient operational liquidity. The company’s larger strategic strategy, which is based on media, technology, and gaming, is in line with this crypto-driven treasury approach.

    Additionally, it is anticipated that the collaboration with influential industry players like Rhydon Lee of Goff Capital and Ryan Zurrer of Dialectic would support ongoing innovation and institutional-level adoption of digital assets. GameSquare has committed to keeping shareholders informed as it progresses with this transformative financial strategy.

  • BTCS Stock Rises On Strategic Ethereum Investment Initiative

    BTCS Stock Rises On Strategic Ethereum Investment Initiative

    After BTCS Inc. (NASDAQ: BTCS) revealed its Ethereum-centric growth strategy, trading activity significantly increased. Shares of BTCS had increased 20.36% to $3.37 as of the most recent trading session.

    Ethereum-First Vision Drives Strategic Expansion

    In order to increase its Ethereum holdings and firmly establish itself as a leader in Ethereum infrastructure among publicly listed corporations, the company announced its intention to raise $100 million by 2025. The foundation of this endeavor is BTCS’s enduring dedication to Ethereum, which it sees as an essential part of the developing digital financial ecosystem.

    Given that Ethereum is already trading close to its 2021 price levels, the business thinks now is a good time to increase its investment. In addition to growing its ETH holdings, BTCS’s strategy is to solidify its standing as a leading provider of blockchain infrastructure.

    Innovative Financing Model Integrates DeFi and TradFi

    BTCS intends to use a combination of traditional financial (TradFi) and decentralized finance (DeFi) processes to carry out its fundraising strategy. At-The-Market (ATM) stock offers, convertible debt issuance, on-chain borrowing through the Aave platform, and Ethereum staking (NodeOps) income generation will all be a part of the finance system. Furthermore, BTCS will pursue vertical integration through Builder+, a block-building solution designed to maximize revenue and increase ETH per share.

    Capital Efficiency and Shareholder Protection Prioritized

    The company emphasized its intent to manage capital conservatively, targeting a net asset value (NAV) leverage cap of 40% across its debt and on-chain borrowings. Subject to advantageous terms, BTCS plans to selectively draw from a convertible financing arrangement with ATW Partners LLC and utilize its $250 million shelf registration under the ATM program. BTCS’s emphasis on reducing dilution, preserving financial flexibility, and increasing long-term shareholder value is reflected in the integrated approach.

    Redefining Blockchain Capital Markets

    BTCS’s strategy represents a novel model for public blockchain firms, merging DeFi innovation with institutional-grade financial tools. Through this hybrid approach, the company aspires to not only grow ETH per share and drive revenues but also establish a benchmark for transparent and sustainable growth in the blockchain sector.

  • Bit Digital (BTBT) Records Upswing After Pivot Toward Ethereum Reserves

    Bit Digital (BTBT) Records Upswing After Pivot Toward Ethereum Reserves

    Bit Digital, Inc. (NASDAQ: BTBT) is on a significant uptick, with shares climbing 19.19% to reach $3.50 as of the last check. The surge followed the company’s announcement of the full execution of its Ethereum-focused treasury strategy.

    Major Treasury Realignment

    The decision came after Bit Digital successfully completed an underwritten public offering, generating approximately $172 million in gross proceeds. A substantial portion of these funds has since been deployed to acquire Ethereum (ETH). In a complementary move, the company also liquidated roughly 280 Bitcoins, reallocating the proceeds toward additional ETH purchases.

    Expanding Ethereum Holdings

    As of March 31, 2025, Bit Digital held 24,434 ETH; this amount has since grown to nearly 100,603 ETH. The increase shows how confident Bit Digital is in Ethereum’s financial and technological potential. The company thinks Ethereum is a game-changer in the developing digital economy because of its programmable structure, growing usage, and staking possibilities.

    Establishing a Focused Ethereum Strategy

    By consolidating its digital asset reserves in Ethereum, Bit Digital aims to position itself as the foremost Ethereum treasury platform among publicly traded entities. The company asserts this strategic pivot will lay the groundwork for its emergence as the largest ETH-holding firm globally. While its current exposure exceeds 100,000 ETH, Bit Digital has expressed intentions to continue expanding its position aggressively.

    Public Offering and Capital Deployment

    The company recently concluded a sizable equity offering to fund its Ethereum initiative. On July 1, 2025, underwriters exercised their full option to purchase an additional 11,250,000 ordinary shares, yielding approximately $21.4 million in net proceeds prior to expenses. With the full allotment exercised, Bit Digital issued a total of 86,250,000 ordinary shares.

    The final net proceeds from the entire offering, inclusive of the additional shares, amounted to roughly $162.9 million. Bit Digital’s decisive treasury realignment reflects a bold commitment to Ethereum’s future as a foundational element of the digital asset space.

  • Digi Power X (DGXX) Shares Advance Following Debt Settlement Agreement

    Digi Power X (DGXX) Shares Advance Following Debt Settlement Agreement

    Digi Power X Inc. (NASDAQ: DGXX) shares are gaining momentum on the charts following the announcement of a key debt settlement agreement. As of the market close, DGXX stock was trading at $3.07, reflecting a 14.55% increase. The rise follows the company’s disclosure of a settlement deal involving the issuance of shares to NANO Nuclear Energy Inc., aimed at addressing outstanding liabilities.

    Debt Settlement to Conserve Cash and Support Growth

    Digi Power X announced that it has reached a final settlement with NANO Nuclear to pay $250,000 in accumulated debts related to consultancy services rendered under a previous MOU signed on December 14, 2024. DGXX will issue 109,677 subordinate voting shares at a presumed price of C$3.10 per share as part of the deal.

    This share offering will be subject to a statutory hold period from the closing date and will not be registered under U.S. securities rules. The completion of the deal necessitates regulatory clearance, including authorization from the TSX Venture Exchange.

    Digi Power X emphasized that the move will safeguard vital cash reserves and enhance its ability to expand its artificial intelligence (AI) and energy infrastructure projects. The strategic financial decision advances DGXX’s main objective of enhancing long-term sustainability and promoting technological innovation.

    SMR Feasibility Study in Progress with NANO Nuclear

    Digi Power X also reaffirmed that it is continuing investigating the feasibility of incorporating small modular reactor (SMR) technology into its data center operations in collaboration with NANO Nuclear. The ongoing effort is to determine if it is practical to use SMRs as a reliable, clean, and scalable power source for AI-driven computer infrastructure.

    Expected Results and Future Prospects

    Digi Power X anticipates reviewing the results of the feasibility study with NANO Nuclear upon completion. DGXX expressed optimism regarding the potential of SMR deployment as a transformative solution for powering its data centers and supporting next-generation AI workloads.

  • Market Buzz: Locafy (LCFY) Soars On U.S. Tech Partnership News

    Market Buzz: Locafy (LCFY) Soars On U.S. Tech Partnership News

    Locafy Limited (NASDAQ: LCFY) witnessed a staggering 247.84% surge in its share price during the latest session, reaching $8.87 at last check. This sharp upswing in stock performance follows the company’s announcement of a strategic partnership.

    Strategic Collaboration

    Locafy (LCFY) today announced a partnership with a leading online reputation and review management platform based in the United States. The collaboration is expected to significantly enhance LCFY’s market presence and product utilization across a range of professional service sectors.

    Empowering Professional Services with AI-Driven Listings

    As part of this partnership, Locafy will syndicate business listings for a premium portion of the partner’s clientele, including real estate agents, mortgage brokers, and various professional service providers.

    The initial implementation spans a substantial share of the partner’s U.S. customer base, laying the groundwork for wider adoption across additional industry verticals. The integration will also enable the partner to expand usage of Locafy’s recently launched AI search and customer engagement technologies.

    AI Search Readiness Takes Center Stage

    An automated, end-to-end content creation process that starts with the company listing is incorporated into Locafy’s solution. Unlike traditional listing syndication, the company’s technology creates proprietary landing pages that are “AI Search Ready.”

    These pages have demonstrated strong visibility on AI platforms such as ChatGPT, Gemini, and Perplexity, where they are frequently cited as primary sources—proof of LCFY’s advanced capabilities in AI search optimization.

    Increasing Digital Visibility and Local SEO

    In addition to content syndication, Locafy is enhancing local pack ranks for high-value keywords utilizing its own AI-powered strategies. The company is providing a compelling solution to assist small companies in increasing their online presence and search engine exposure by fusing scalable technology, AI-optimized landing pages, and syndicated listings.

    This strategic partnership improves Locafy’s standing at home while also offering a sizable business prospect in the US market. In order to support its mission to grow internationally, establish stronger tech collaborations, and create revolutionary digital marketing solutions suited to a search-first digital world, LCFY wants to offer a smooth upgrade path for clients to its larger suite of AI search capabilities.

  • AIRO Gains Market Attention After Concluding Key Military Support Mission

    AIRO Gains Market Attention After Concluding Key Military Support Mission

    AIRO Group Holdings, Inc. (NASDAQ: AIRO) shares are rising significantly in U.S. trading today, advancing 12.74% to $24.69 at the last check. The surge follows the company’s announcement of the successful conclusion of a high-impact 90-day training support mission for Naval Special Warfare (NSW). This milestone adds to the robust revenue growth seen throughout 2024 and the first half of 2025 in AIRO’s military training division.

    Sustained Defense Support Across U.S. Regions

    As a specialized provider of training for elite military forces, AIRO has continued its role supporting the U.S. Navy and Marine Corps’ Joint Terminal Attack Controller (JTAC) program. Utilizing its fleet of fighter jets and specially modified twin-engine Cessna aircraft, the company executed hundreds of Close Air Support (CAS) missions across California, Idaho, and Nevada.

    These activities were conducted under multiple award Indefinite Delivery Indefinite Quantity (IDIQ) contracts, including the Terminal Attack Controller Trainer (TACT) and Naval Special Warfare Air Support initiatives.

    Global Recognition and Strategic Contract Awards

    Amid global instability and ongoing conflict in more than 60 regions, AIRO has emerged as a critical partner to the U.S. Department of Defense and allied defense forces. The company’s inclusion in the $5.7 billion Combat Air Force/Commercial Air Service (CAF CAS II) IDIQ contract highlights its reputation for reliability and innovation in mission-focused solutions.

    AIRO extended its Intelligence, Surveillance, and Reconnaissance (ISR) and CAS activities in early 2025 to support significant Air National Guard exercises as well as regular readiness.

    Expanding Capabilities and International Training Reach

    To date, AIRO has secured over $30 million in direct NSW support contracts, providing advanced ISR platforms, full-motion video capabilities, live munitions, dynamic unmanned targets, and CAS expertise. Its brand, ‘Coastal Defense,’ remains central to delivering realistic training for tier-one operators.

    AIRO is also preparing for a major international exercise, deploying over 50 remotely controlled ground targets and eight specialized control teams, further reinforcing its global role in operational readiness and inter-service coordination.

  • Profound Medical (PROF) Sees After-Hour Stock Boost On Commercial Milestone

    Profound Medical (PROF) Sees After-Hour Stock Boost On Commercial Milestone

    Following an announcement of a critical milestone in the commercialization of its flagship technology, Profound Medical Corp. (NASDAQ: PROF) shares saw notable rises on Tuesday. During regular trading, PROF stock rose 17.39% to conclude at $6.75, while after-hours trading saw a further 5.78% climb to $7.14.

    Breakthrough Milestone

    The rally came in response to the announcement that the first commercial patient had been treated using the company’s advanced TULSA-AI Volume Reduction Module, designed for benign prostatic hyperplasia (BPH).

    Profound Medical verified that Dr. Naveen Kella of The Urology Place in San Antonio successfully completed the first commercial TULSA treatment utilizing the AI-based module. Lower urinary tract symptoms (LUTS), which are frequently caused by benign prostatic hyperplasia (BPH), have a substantial negative impact on quality of life.

    Conventional therapies, such as transurethral resection of the prostate (TURP), have not evolved much in a century and are linked to concerns including erectile dysfunction, bleeding, and extensive recovery periods.

    Innovative, AI-Driven Procedure

    The TULSA-PRO system, now enhanced by the TULSA-AI Volume Reduction Module, offers a minimally invasive, incision-free solution that preserves urinary and sexual function while reducing obstructive prostate tissue.

    Utilizing real-time MRI and artificial intelligence, the procedure tailors treatment based on each patient’s unique anatomy. The new module optimizes treatment planning and ablation precision, reducing total procedure time to 60–90 minutes and eliminating the need for hospital stays.

    Market Expansion and Clinical Impact

    With this technological advancement, Profound Medical is poised to significantly expand its market reach. Moreover, clinical findings, including data from the University of Turku, highlight improvements in patient outcomes such as symptom relief, urinary flow, and medication discontinuation—positioning TULSA-AI as a potential game-changer in prostate care.

    The TULSA-AI enhancement aims to address the previous barrier of longer procedure times for BPH-only patients. Now, Profound Medical projects an increase in its annual market opportunity from 200,000 to 600,000 treatable cases.